In a joint statement Danish drugmaker Novo Nordisk and U.S. drug developer Prothena Corp said, the former will acquire the latter’s experimental heart therapy PRX004, in a deal that could be worth up to $1.23 billion. Novo’s acquisition is in… Read More ›
Warning against excessive transparency, Novo Nordisk said the upcoming transparency bills could impact its growth potential in key markets. On Wednesday, drugmaker Novo Nordisk warned that the new legislation being prepared in some states in the U.S. which are aimed… Read More ›
manageria.biz 